Observational retrospective analysis of vaccination against SARS-CoV-2 and seizures: VACCI-COVID registry.

BACKGROUND: We aimed to assess the risk of developing new-onset seizures or seizure decompensations in people with epilepsy (PWE) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. METHODS: A retrospective observational study in a tertiary hospital was conducted. Clinical records of all patients attended because of seizures or epilepsy at outpatient clinics, emergency department, or admitted to our hospital from January to December 2021 were reviewed, including patients older than 16 years who received some dose of coronavirus disease 2019 (COVID-19) vaccines. RESULTS: A total of 418 vaccinated PWE were analyzed: 6.2% presented an increase in seizure frequency and 1% reported different seizure types during the next month after vaccination. However, 61.5% had another possible cause for this decompensation. Having monthly seizures (1-3/month) was the only associated risk factor (OR 4.9, p < 0.001) while being seizure free > 1 year had a protective role (OR 0.36, p = 0.019). Patients with epileptic encephalopathies or a history of COVID-19 infection were not at increased risk of seizure decompensation. Besides this, 15 patients presented new-onset seizures within the first month post-vaccination, mean time from vaccination 15 ±â€¯8 days, 67% after the second dose. Again, 53.3% had another possible trigger for seizures. Eight debuted with status epilepticus or cluster of seizures. CONCLUSIONS: A small proportion of PWE (6.2%) had an increase in seizure frequency after COVID-19 vaccination and 15 patients had new-onset seizures during the first month after vaccination, though another reason for seizure exacerbation was identified in 61.5% and 53.3%, respectively. Severe acute respiratory syndrome COVID-19 vaccines appear to have little impact on the generation or decompensation of seizures.

Advanced interatrial block: An electrocardiographic marker for stroke recurrence.

The presence of interatrial block (IAB) has been directly related to the appearance of various atrial tachyarrhythmias and therefore could be a risk factor for stroke. The objective of this study is to establish whether the presence of IAB could predict stroke recurrence in patients with a previous episode. METHODS: We included all patients discharged from our hospital in 2011 following treatment for stroke, excluding those of cardioembolic or lacunar etiology. For all patients we analyzed the ECG recordings, determined whether the patient presented cardiovascular risk factors, and determined the presence and type of IAB. An IAB was defined as partial if the P-wave duration was ≥120 ms, and advanced if the duration was ≥120 ms and presented biphasic morphology in the inferior leads. The primary endpoint was the recurrence of stroke and the secondary endpoint was the incidence of atrial tachyarrhythmias after the first episode. RESULTS: A total of 149 patients were identified (80 (71.5-86.0) years, 41% men). After a median follow-up of 3.96 (0.63-5.35) years, 54 deaths (36%) were observed, 27 patients (18%) had experienced stroke recurrence, and 20 (13%) had developed atrial tachyarrhythmias. On multivariate analysis, the presence of advanced IAB [HR: 2.3, 95% CI (1.0-5.5); p = 0.043] and diabetes [HR: 2.5, 95% CI (1.1-5.4); p = 0.018] were significantly associated with stroke recurrence. CONCLUSION: The presence of advanced IAB predicts the recurrence of stroke in patients with a previous episode. Further studies should be performed to investigate possible interventions.

Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change.

Migraine-related stigma is a pervasive issue impacting nearly half of chronic migraine patients, with significant consequences for their quality of life, disability and mental health. Despite its profound effects, migraine stigma remains under-recognised in both clinical practice and research. This narrative review explores the three primary types of stigmas affecting migraine patients: public, structural and internalised. Public stigma involves negative societal attitudes and stereotypes that trivialise the condition. Structural stigma is reflected in policies that restrict access to necessary care and resources. Internalised stigma occurs when patients absorb these negative views, leading to self-blame and diminished self-worth. Addressing these different types of stigmas is crucial for improving the understanding, diagnosis and treatment of migraine. Educational efforts, advocacy and policy reform are essential strategies in this context. A deep understanding of stigma is vital for developing effective interventions that enhance clinical management and patient quality of life. Ultimately, reducing stigma can lead to better health outcomes and a more comprehensive approach to migraine care.